Trial Profile
Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms AGAC2
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 22 Nov 2011 New trial record